CD19 and acute lymphoblastic leukemia: Thus, we conducted a phase II clinical trial applying IL-6 knocking down anti-CD19 CAR-T cells to products designed for safety (termed as ssCAR-T-19) for treating 61 patients with r/r B-ALL.